These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26842912)

  • 61. The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by α-PD-L1 or α-IL6 antibodies.
    Rolvering C; Zimmer AD; Ginolhac A; Margue C; Kirchmeyer M; Servais F; Hermanns HM; Hergovits S; Nazarov PV; Nicot N; Kreis S; Haan S; Behrmann I; Haan C
    J Leukoc Biol; 2018 Nov; 104(5):969-985. PubMed ID: 30040142
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Proinflammatory S100A8 Induces PD-L1 Expression in Macrophages, Mediating Tumor Immune Escape.
    Li Z; Wang J; Zhang X; Liu P; Zhang X; Wang J; Zheng X; Wei L; Peng Q; Liu C; Yan Q; Shen S; Li X; Ma J
    J Immunol; 2020 May; 204(9):2589-2599. PubMed ID: 32198140
    [TBL] [Abstract][Full Text] [Related]  

  • 63. CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.
    Zeisbrich M; Chevalier N; Sehnert B; Rizzi M; Venhoff N; Thiel J; Voll RE
    Front Immunol; 2021; 12():673912. PubMed ID: 34108971
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
    Noguchi T; Ward JP; Gubin MM; Arthur CD; Lee SH; Hundal J; Selby MJ; Graziano RF; Mardis ER; Korman AJ; Schreiber RD
    Cancer Immunol Res; 2017 Feb; 5(2):106-117. PubMed ID: 28073774
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oxygen Saturation on Admission Is a Predictive Biomarker for PD-L1 Expression on Circulating Monocytes and Impaired Immune Response in Patients With Sepsis.
    Avendaño-Ortiz J; Maroun-Eid C; Martín-Quirós A; Lozano-Rodríguez R; Llanos-González E; Toledano V; Gómez-Campelo P; Montalbán-Hernández K; Carballo-Cardona C; Aguirre LA; López-Collazo E
    Front Immunol; 2018; 9():2008. PubMed ID: 30233593
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ataxia telangiectasia mutated kinase inhibition promotes irradiation-induced PD-L1 expression in tumour-associated macrophages through IFN-I/JAK signalling pathway.
    Gao Y; Li Y; Lin Z; Zeng Y; Huang Z; Han L; Zhong Y; Gong Y; Wu Q; Xie C
    Immunology; 2023 Feb; 168(2):346-361. PubMed ID: 36326481
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.
    Cascio MJ; Whitley EM; Sahay B; Cortes-Hinojosa G; Chang LJ; Cowart J; Salute M; Sayour E; Dark M; Sandoval Z; Mitchell DA; Milner RJ
    Vet Immunol Immunopathol; 2021 Feb; 232():110169. PubMed ID: 33387703
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.
    Maekawa N; Konnai S; Ikebuchi R; Okagawa T; Adachi M; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Murata S; Ohashi K
    PLoS One; 2014; 9(6):e98415. PubMed ID: 24915569
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.
    Martin V; Chiriaco C; Modica C; Acquadro A; Cortese M; Galimi F; Perera T; Gammaitoni L; Aglietta M; Comoglio PM; Vigna E; Sangiolo D
    Br J Cancer; 2019 Mar; 120(5):527-536. PubMed ID: 30723303
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
    Blank C; Kuball J; Voelkl S; Wiendl H; Becker B; Walter B; Majdic O; Gajewski TF; Theobald M; Andreesen R; Mackensen A
    Int J Cancer; 2006 Jul; 119(2):317-27. PubMed ID: 16482562
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Blocking of checkpoint receptor PD-L1 aggravates osteoarthritis in macrophage-dependent manner in the mice model.
    Liu S; Mi J; Liu W; Xiao S; Gao C
    Int J Immunopathol Pharmacol; 2019; 33():2058738418820760. PubMed ID: 30791745
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.
    Qu QX; Huang Q; Shen Y; Zhu YB; Zhang XG
    Tumour Biol; 2016 Apr; 37(4):5031-7. PubMed ID: 26541760
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice.
    Hu JF; Zhang W; Zuo W; Tan HQ; Bai W
    Pulm Pharmacol Ther; 2020 Feb; 60():101842. PubMed ID: 31541762
    [TBL] [Abstract][Full Text] [Related]  

  • 74. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Potential Inhibitory Profile of Liver CD68+ Cells during HCV Infection as Observed by an Increased CD80 and PD-L1 but Not CD86 Expression.
    Said EA; Al-Reesi I; Al-Riyami M; Al-Naamani K; Al-Sinawi S; Al-Balushi MS; Koh CY; Al-Busaidi JZ; Idris MA; Al-Jabri AA
    PLoS One; 2016; 11(4):e0153191. PubMed ID: 27065104
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
    Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
    Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
    Majzner RG; Simon JS; Grosso JF; Martinez D; Pawel BR; Santi M; Merchant MS; Geoerger B; Hezam I; Marty V; Vielh P; Daugaard M; Sorensen PH; Mackall CL; Maris JM
    Cancer; 2017 Oct; 123(19):3807-3815. PubMed ID: 28608950
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Exosomes from Melatonin Treated Hepatocellularcarcinoma Cells Alter the Immunosupression Status through STAT3 Pathway in Macrophages.
    Cheng L; Liu J; Liu Q; Liu Y; Fan L; Wang F; Yu H; Li Y; Bu L; Li X; Wei W; Wang H; Sun G
    Int J Biol Sci; 2017; 13(6):723-734. PubMed ID: 28655998
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.
    Yamashita K; Iwatsuki M; Yasuda-Yoshihara N; Morinaga T; Nakao Y; Harada K; Eto K; Kurashige J; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Baba Y; Miyamoto Y; Yoshida N; Ajani JA; Baba H
    Br J Cancer; 2021 Feb; 124(3):595-603. PubMed ID: 33100329
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.